Healthequity (NASDAQ:HQY) Rating Reiterated by KeyCorp

Healthequity (NASDAQ:HQY)‘s stock had its “buy” rating reiterated by equities researchers at KeyCorp in a research note issued to investors on Wednesday, reports. They presently have a $77.00 target price on the stock, up from their previous target price of $70.00. KeyCorp’s target price would suggest a potential upside of 25.73% from the stock’s current price.

HQY has been the subject of several other research reports. BidaskClub upgraded shares of Healthequity from a “sell” rating to a “hold” rating in a research report on Wednesday, November 6th. Oppenheimer dropped their target price on shares of Healthequity from $98.00 to $76.00 and set an “outperform” rating on the stock in a report on Wednesday, September 4th. Raymond James raised shares of Healthequity from an “outperform” rating to a “strong-buy” rating and cut their target price for the company from $90.00 to $80.00 in a research note on Monday, September 9th. Zacks Investment Research upgraded shares of Healthequity from a “sell” rating to a “buy” rating and set a $62.00 target price for the company in a report on Tuesday, November 5th. Finally, Deutsche Bank assumed coverage on shares of Healthequity in a report on Thursday, September 12th. They set a “buy” rating and a $74.00 target price for the company. Three research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $77.86.

HQY opened at $61.24 on Wednesday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 22.98 and a current ratio of 22.98. The company has a market capitalization of $4.44 billion, a PE ratio of 64.46, a P/E/G ratio of 2.87 and a beta of 1.47. The stock’s fifty day moving average is $59.78 and its 200-day moving average is $64.21. Healthequity has a one year low of $50.29 and a one year high of $91.19.

Healthequity (NASDAQ:HQY) last announced its earnings results on Tuesday, December 3rd. The company reported $0.47 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.14 by $0.33. The business had revenue of $157.12 million during the quarter, compared to analysts’ expectations of $152.38 million. Healthequity had a return on equity of 11.77% and a net margin of 28.13%. The company’s quarterly revenue was up 122.9% on a year-over-year basis. During the same quarter last year, the business posted $0.25 earnings per share. On average, equities research analysts forecast that Healthequity will post 0.87 EPS for the current fiscal year.

In other news, CFO Darcy G. Mott sold 4,000 shares of Healthequity stock in a transaction that occurred on Friday, September 20th. The shares were sold at an average price of $61.61, for a total value of $246,440.00. Following the transaction, the chief financial officer now directly owns 46,000 shares of the company’s stock, valued at $2,834,060. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Over the last three months, insiders sold 12,000 shares of company stock worth $715,600. 3.70% of the stock is currently owned by insiders.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. grew its holdings in shares of Healthequity by 13.1% during the second quarter. BlackRock Inc. now owns 7,268,685 shares of the company’s stock valued at $475,373,000 after buying an additional 840,177 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Healthequity by 2.5% during the 2nd quarter. Vanguard Group Inc. now owns 5,646,295 shares of the company’s stock worth $369,268,000 after acquiring an additional 138,020 shares in the last quarter. State Street Corp lifted its holdings in Healthequity by 18.7% in the 3rd quarter. State Street Corp now owns 2,189,161 shares of the company’s stock worth $125,100,000 after purchasing an additional 344,173 shares during the last quarter. Invesco Ltd. boosted its position in Healthequity by 13.7% during the second quarter. Invesco Ltd. now owns 2,140,851 shares of the company’s stock worth $140,012,000 after purchasing an additional 258,769 shares during the period. Finally, Janus Henderson Group PLC boosted its position in Healthequity by 13.9% during the second quarter. Janus Henderson Group PLC now owns 2,057,831 shares of the company’s stock worth $134,582,000 after purchasing an additional 250,692 shares during the period. Institutional investors own 95.84% of the company’s stock.

Healthequity Company Profile

HealthEquity, Inc provides various solutions for managing health care accounts, health reimbursement arrangements, and flexible spending accounts for health plans, insurance companies, and third-party administrators in the United States. The company offers healthcare saving and spending platform, a cloud-based platform for individuals to make health saving and spending decisions, pay healthcare bills, compare treatment options and prices, receive personalized benefit and clinical information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.

Featured Article: Shanghai Stock Exchange Composite Index

Analyst Recommendations for Healthequity (NASDAQ:HQY)

Receive News & Ratings for Healthequity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Healthequity and related companies with's FREE daily email newsletter.


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit